We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Liposomal Doxorubicin and Docetaxel in HER2 Negative Metastatic Breast Cancer (MYOTAX)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00377559
First Posted: September 18, 2006
Last Update Posted: October 6, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
Cephalon
Sanofi
Information provided by:
Catharina Ziekenhuis Eindhoven
  Purpose
This is an open phase II multicentre study evaluating the efficacy and safety of the non pegylated liposomal doxorubicin (Myocet®) and docetaxel (Taxotere®) combination as first-line treatment of patients with metastatic HER2/neu negative breast cancer.

Condition Intervention Phase
Breast Cancer Neoplasm Metastasis Drug: Non pegylated liposomal doxorubicin and docetaxel Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Multicentre Open Label Trial Evaluating the Efficacy and Safety of the Liposomal Doxorubicin (Myocet®) and Docetaxel (Taxotere®) Combination as First-line Treatment of Patients With Metastatic HER2/Neu Negative Breast Cancer

Resource links provided by NLM:


Further study details as provided by Catharina Ziekenhuis Eindhoven:

Primary Outcome Measures:
  • Cardiotoxicity (definite or probable cardiac death) [ Time Frame: treatment period ]
  • Signs or symptoms of congestive heart failure (CHF), New York Heart Association (NYHA) class III-IV [ Time Frame: treatment period ]
  • Decline in left ventricular ejection fraction (LVEF) of ≥ 5% to < 50% with mild signs or symptoms of CHF (NYHA class < III) [ Time Frame: treatment period ]
  • Decline in LVEF of ≥ 10% to < 50% without signs or symptoms of CHF [ Time Frame: treatment period ]

Secondary Outcome Measures:
  • Frequency and severity of intercurrent events according to the National Cancer Institute - Common Terminology Criteria (NCI-CTC) classification [ Time Frame: treatment period ]
  • Response rate [ Time Frame: treatment period ]
  • Median time to progression [ Time Frame: treatment period ]
  • Progression free survival [ Time Frame: treatment period ]

Enrollment: 70
Study Start Date: May 2006
Study Completion Date: July 2011
Primary Completion Date: November 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1.
Myocet+docetaxel
Drug: Non pegylated liposomal doxorubicin and docetaxel
max. 6 courses
Other Name: Myocet, Taxotere

Detailed Description:

Phase II non comparative study, assessing the safety (primarily cardiac safety) and efficacy in patients with locally advanced or metastatic HER2/neu negative breast cancer not yet treated with chemotherapy for metastatic disease.

Myocet and Taxotere will be given for a maximum of 6 cycles. Endpoints: cardiotoxicity (left ventricular ejection fraction decrease and/or symptoms of heart failure), serious other toxicity, disease progression.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Women with histologically documented metastatic or locally advanced metastatic HER2/neu negative breast cancer.
  • In the case of previous adjuvant or neoadjuvant chemotherapy with anthracyclines or taxanes, this must have been completed more than 12 months before inclusion.
  • In the case of previous adjuvant or neoadjuvant chemotherapy, cumulative anthracycline dose ≤ 360 mg/m2 of doxorubicin or 600 mg/m2 of epirubicin or 75 mg/m2 of mitoxantrone on inclusion.
  • Previous endocrine therapy is authorized (endocrine therapy other than goserelin must be stopped before starting treatment).
  • Previous radiotherapy is authorized, if discontinued ≥ 4 weeks prior to inclusion in the study and if < 10% of the bone marrow was within the irradiated area.
  • Age ≥ 18 years.
  • Performance status 0,1, or 2.
  • Life expectancy ≥ 3 months.
  • Evaluable disease.
  • Normal LVEF (multigated acquisition [MUGA] scan or echocardiography).
  • Normal haematological, hepatic and renal parameters: neutrophils ≥ 1.5 x 10^9/l; platelets ≥ 100 x 10^9/l; hemoglobin (Hb) ≥ 6 mmol/L; total bilirubin ≤ 1.5 times the upper limit of normal (ULN); transaminases ≤ 2.5 x ULN; alkaline phosphatase ≤ 2.5 x ULN; creatinine ≤ 1.5 x ULN.
  • Dated and signed written informed consent.

Exclusion Criteria:

  • Previous chemotherapy for metastatic disease.
  • History of other cancer, except for cervical carcinoma in situ treated by cone resection or basal cell or squamous cell skin cancer.
  • History of congestive heart failure or myocardial infarction ≤ 1 year; cardiac function: NYHA ≥ 2 or LVEF < 50%. Uncontrolled significant heart disease, such as unstable angina.
  • Poorly controlled hypertension.
  • Performance status 3, 4.
  • Symptomatic or progressive brain metastases.
  • Active infection or other serious underlying disease.
  • Concomitant participation in other clinical trials.
  • Pregnant women or nursing mothers; patients of childbearing potential without effective contraception.
  • Absolute medical contraindication to the use of corticosteroid premedication.
  • Allergy to polysorbate 80, doxorubicin, or egg lecithin.
  • NCI-CTC grade > 1 peripheral neuropathy.
  • Patients not able to comply with regular medical follow-up
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00377559


Locations
Netherlands
Jeroen Bosch Ziekenhuis
's-Hertogenbosch, Netherlands, 5211 NL
Wilhelmina Ziekenhuis
Assen, Netherlands, 9400 RA
Catharina-Ziekenhuis
Eindhoven, Netherlands, 5602 ZA
Ikazia Ziekenhuis
Rotterdam, Netherlands, 3083 AN
Sint Elisabeth Ziekenhuis
Tilburg, Netherlands, 5000 LC
Mesos Medisch Centrum
Utrecht, Netherlands, 3527 CE
Maxima Medisch Centrum
Veldhoven, Netherlands, 5500 MB
VieCuri MC
Venlo, Netherlands, 5900 BX
Ziekenhuis Walcheren
Vlissingen, Netherlands, 4380 DD
Streekziekenhuis Koningin Beatrix
Winterswijk, Netherlands, 7100 GG
Sponsors and Collaborators
Catharina Ziekenhuis Eindhoven
Cephalon
Sanofi
Investigators
Principal Investigator: Laurence J. van Warmerdam, MD, PhD Catharina-Ziekenhuis
  More Information

Responsible Party: Raymond J.P. Schmidt, MD, Stichting (Foundation) BO3
ClinicalTrials.gov Identifier: NCT00377559     History of Changes
Other Study ID Numbers: MYOTAX
First Submitted: September 15, 2006
First Posted: September 18, 2006
Last Update Posted: October 6, 2015
Last Verified: August 2011

Keywords provided by Catharina Ziekenhuis Eindhoven:
Breast cancer
metastatic
cardiotoxicity
liposomal
doxorubicin
docetaxel
HER2/neu negative metastatic breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasm Metastasis
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Neoplastic Processes
Pathologic Processes
Docetaxel
Liposomal doxorubicin
Doxorubicin
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antibiotics, Antineoplastic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors